ATOH8 and prostate carcinoma: By exploring Oncomine data base [32], we found that ATOH8 decreased expression in bladder cancer, breast cancer, lung cancer, ovarian cancer and prostate cancer, whereas it increased expression in brain and CNS cancer and esophageal cancer, suggesting the divergent function of ATOH8 in human cancers.